- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05413915
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
A Phase 3, Multicenter, Randomized, Open-Label, Trial Evaluating the Efficacy and Safety of Asciminib Used in Consolidation With Imatinib v. Imatinib to Achieve Treatment-free Remission in Chronic Phase-Chronic Myelogenous Leukemia Patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Caroline Lambert, PhD
- Phone Number: 23628 514-340-8222
- Email: clambert@jgh.mcgill.ca
Study Contact Backup
- Name: Chadi Zakaria, PhD
- Phone Number: 28326 514-340-8222
- Email: chadi.zakaria.ccomtl@ssss.gouv.qc.ca
Study Locations
-
-
-
Québec, Canada, G1J 1Z4
- Recruiting
- Hôpital Enfant-Jésus - CHUQ
-
Contact:
- Michèle Tremblay
-
Principal Investigator:
- Robert Delage, MD
-
-
Quebec
-
Montreal, Quebec, Canada, H3T1E2
- Recruiting
- Clinical Research Unit - Jewish General Hospital
-
Principal Investigator:
- Sarit Assouline, MD
-
Contact:
- Maria Kluchnyk
- Phone Number: 26394 1-514-340-8222
- Email: maria.kluchnyk.ccomtl@ssss.gouv.qc.ca
-
Montréal, Quebec, Canada, H1T 2M4
- Recruiting
- Hôpital Maisonneuve-Rosemont (CIUSSS EMTL)
-
Contact:
- Michaël Harnois
- Email: mharnois.hmr@ssss.gouv.qc.ca
-
Principal Investigator:
- Lambert Busque, MD
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Recruiting
- Hôpital Fleurimont - CHUS (CIUSSS Estrie)
-
Contact:
- Anick Champoux
-
Principal Investigator:
- Vincent Éthier, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
In order to be eligible, candidates must fulfill all the following criteria:
- Male or female patients aged at least 18 years of age with a confirmed diagnosis of CML-CP.
- Written informed consent prior to any screening procedures
- Available and willing to comply with all study assessments.
Imatinib treatment ongoing > 4 years, and currently receiving:
- Standard dose 400 mg PO QD or;
- 300 mg PO QD for at least 6 months (see below)
- CML in deep molecular response (DMR, at least MR4 IS) for at least 12 months prior to randomization (documented through at least 3 PCRs test results over the period of 12 months prior to randomization, showing BCR-ABL1 levels ≤ 0.01% IS (International Scale) and no result over >0.01%). For patients receiving 300 mg imatinib QD, minimum of two (2) of those qPCRs evaluations must have been obtained at least 3 months apart while on 300 mg imatinib.
- ECOG performance status of 0-2.
Adequate organ function, defined by:
- Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9/L
- Platelets ≥ 75 x 10^9/L (without the requirement for transfusion for 14 days)
- Hemoglobin ≥ 90 g/L (without the requirement for transfusion for 14 days)
- Serum creatinine < 132 µmol/L
- Total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's syndrome who may only be included with total bilirubin ≤ 3.0 x ULN)
- Aspartate transaminase (AST) ≤ 3.0 x ULN
- Alanine transaminase (ALT) ≤ 3.0 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN
- Serum lipase ≤ 1.5 x ULN
Serum levels of potassium, magnesium, total calcium within the normal laboratory range. Correction of electrolytes levels with supplements to fulfil enrolment criteria is allowed.
- potassium increase of up to 6.0 mmol/L is acceptable if associated with creatinine clearance within normal limits (as estimated by the Cockcroft-Gault formula, appendix 1)
- calcium increase to 3.1 mmol/L is acceptable if associated with creatinine clearance within normal limits
- magnesium increase up to 1.23 mmol/L if associated with creatinine clearance within normal limits
- No previous CML-AP/BP by MDACC criteria nor resistance to TKI by ELN criteria.
- Never attempted TFR
Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must have a negative serum pregnancy test before initiation of study treatment, and must also use highly effective methods of contraception to continue for at least 14 days after the last dose of study treatment, or for the duration of a monthly cycle of oral contraception, whichever is longer. Acceptable forms of highly effective contraception methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- Male/female sterilization defined as: 1. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed and documented by follow up hormone level assessment 2. Male sterilization of the sole partner (at least 6 months prior to screening) of a female patient on the study.
- A combination of any two of the following (i+ii or i+iii or ii+iii): i) Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository ii) Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception iii) Placement of an intrauterine device (IUD) or intrauterine system (IUS)
Exclusion Criteria:
- Patients known to be in second CP-CML after previous progression to AP/BC-CML
- Previous treatment with a TKI other than imatinib.
- Prior allogeneic transplant.
- Tolerance concerns to continue imatinib on study, as determined by the investigator.
- Treatment with strong inducers/inhibitors of CYP3A4.
- Known atypical ABL1-BCR transcript that precludes use of IS system for monitoring.
Current or prior history of another malignancy within the past 2 years, unless it is a solid tumor with a life expectancy of at least 3 years and its treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (for example, patients who have undergone complete resection of an in situ carcinoma, or who have a low risk indolent prostate cancer are eligible). History or current diagnosis of cardiac disease indicating significant risk or safety for subjects participating in the study such as:
- History of myocardial infarction, angina pectoris, coronary artery bypass graft within 6 months prior to randomization
- Concomitant clinically significant arrhythmias
- Resting QTcF ≥ 450 msec (male) or ≥ 460 msec (female) prior to randomization
- Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
i. Risk factors for Torsades de Pointes ii. Concomitant medications with a "known" risk of Torsades de Pointes iii. inability to accurately determine the QTcF interval, unless this is due to the presence of a pacemaker.
- History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis; on-going acute liver disease or history of chronic liver disease
- Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- Subjects with other severe or uncontrolled medical conditions that in the opinion of the investigator may compromise their compliance with the protocol or may represent an unacceptable risk to their safety (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled clinically significant hyperlipidemia and high serum amylase).
- Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1.
- Known allergy or hypersensitivity to asciminib or any of its excipients.
- Patients who are pregnant or breastfeeding or WOCBP not employing an effective method of birth control.
- Known infection with Human Immunodeficiency virus (HIV), chronic Hepatitis B (HBV) or chronic hepatitis C infection (HCV). Hepatitis B and C testing will be performed at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Imatinib
Standard of care imatinib at 300 or 400 mg PO daily for 52 weeks
|
Tyrosine kinase inhibitor
Other Names:
|
Experimental: Imatinib and Asciminib
Asciminib (60 mg PO daily for 52 weeks) will be added to standard of care imatinib (300 or 400 mg PO daily for 52 weeks)
|
Tyrosine kinase inhibitor
Other Names:
Tyrosine kinase inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free survival rate
Time Frame: randomization until 12 months after discontinuation of all TKI among randomized patients
|
Occurrence of death or loss of deep molecular response (DMR, MR4 (4-log reduction in BCR-ABL1 or better)) or loss of major molecular response (MMR, MR3 (3-log reduction in BCR-ABL1)) at any time.
|
randomization until 12 months after discontinuation of all TKI among randomized patients
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Molecular relapse free rate
Time Frame: TKI discontinuation until loss of MR3 (up to 1 year)
|
Sustained MR3 status at 12 months among patients who attempt TFR
|
TKI discontinuation until loss of MR3 (up to 1 year)
|
Event-free survival rate
Time Frame: randomization to 6 months after discontinuation of TKI among all randomized patients
|
Occurrence of death or "molecular relapse" as defined as any loss of MR4 status during the Consolidation period OR any loss of MR3 by qPCR at any time
|
randomization to 6 months after discontinuation of TKI among all randomized patients
|
Time to molecular relapse
Time Frame: Tyrosine kinase inhibitor (TKI) discontinuation until loss of MR3 (up to 1 year)
|
Time in months to loss of MR3 among subjects who attempt treatment-free remission (TFR)
|
Tyrosine kinase inhibitor (TKI) discontinuation until loss of MR3 (up to 1 year)
|
Cumulative incidence of adverse events grade ≥ 3 in each arm, using CTCAE 5.0
Time Frame: from first dose/randomization until 30 days post last dose
|
Safety and tolerability of asciminib when used with imatinib
|
from first dose/randomization until 30 days post last dose
|
Association between duration of prior imatinib exposure and TFR (Treatment Free Remission) as assessed by Hazard Ratio
Time Frame: from randomization until up to 12 months post consolidation
|
from randomization until up to 12 months post consolidation
|
|
Association between duration of deep molecular response (DMR) and TFR (Treatment Free Remission) as assessed by Hazard Ratio
Time Frame: from randomization until up to 12 months post consolidation
|
from randomization until up to 12 months post consolidation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sarit E Assouline, MD, MSc, SMBD Jewish General Hospital CIUSSS West Central Montreal
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Chronic Disease
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
Other Study ID Numbers
- QC-TFR1-ABL001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Bristol-Myers SquibbTerminatedLeukemia, Myeloid, ChronicSweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
-
University of BolognaCompletedMyeloid Leukemia, Chronic, Chronic-PhaseItaly
-
Bristol-Myers SquibbWithdrawnMyeloid Leukemia, Chronic, Chronic-PhaseUnited States
-
PETHEMA FoundationCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
Emory UniversityTerminatedLeukemia | Chronic Myeloid Leukemia | Chronic Myelogenous LeukemiaUnited States
Clinical Trials on Imatinib
-
Scandinavian Sarcoma GroupCompleted
-
Centre Leon BerardCompletedGastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene MutationFrance
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina
-
Seoul St. Mary's HospitalNovartisUnknownChronic Myeloid LeukemiaKorea, Republic of
-
M.D. Anderson Cancer CenterNovartisCompletedGastrointestinal Stromal TumorsUnited States
-
Novartis PharmaceuticalsCompletedGastrointestinal Stromal TumorsUnited States, France, Belgium, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMelanoma | Skin NeoplasmsUnited States
-
University of Auckland, New ZealandLeukaemia & Blood Cancer New ZealandActive, not recruiting
-
Novartis PharmaceuticalsCompletedPulmonary Arterial HypertensionAustria, Germany, United States, United Kingdom
-
Novartis PharmaceuticalsTerminatedMyelogenous LeukemiaUnited States, Germany, Belgium, Italy, Spain, Korea, Republic of, Brazil, Japan, Australia, Czech Republic